Over time
China over time. Forecasts are dashed with hollow markers; the underlying values are one click away under the chart.
First-in-class drug approvals
China, 2022 to 2025
Every record
9 records · 1 region · 2022–2025. Each period links to its record: the value, its source evidence and original document.
| Period | Value | Source | Type |
|---|---|---|---|
| China 9 records | |||
| 2025 | 11 | NHSA · 31 Dec 2025 | |
| 2025 | 11 | MOFCOM · 31 Dec 2025 | |
| 2024 | 48 | State Council · 31 Dec 2024 | |
| 2024 | 48 | NMPA · 31 Dec 2024 | |
| 2024 | 48 | NMPA · 31 Dec 2024 | |
| 2023 | 40 | State Council · 31 Dec 2023 | |
| 2023 | 40 | NMPA · 31 Dec 2023 | |
| 2022 | 21 | State Council · 31 Dec 2022 | |
| 2022 | 21 | NMPA · 31 Dec 2022 | |
Download this data
Every file carries its provenance: the CSV has a source column per row, and the chart images print the publisher, the licence and this page's address under the drawing. Source: NHSA, MOFCOM, State Council and 1 more. Licence: CC BY 4.0.
Embed this chart
For automatic sizing and multiple charts, see the JavaScript embed guide.
Free to embed anywhere, including commercially. The attribution bar is part of the chart. The link under the frame is optional: keep it, remove it or mark it rel="nofollow".
Use and publication rights
- View, cite and link: free
Quote any number, cite this page or a single record, and link to it anywhere.
- Copy, chart and republish: free with attribution
The data is published under CC BY 4.0, commercial use included. Credit StatOrigin and the original publisher (NHSA, MOFCOM, State Council and 1 more); the chart files already carry that line.
- The source documents: the publisher's terms
Figures are facts read from the publishers' own documents. The documents themselves, their text and design, stay under each publisher's terms; follow the source links for those.
How this measure is built
- Definition
- Number of approved therapeutic drugs featuring a novel biological mechanism of action.
- Measure
- One slice of Drug approvals ( form: count, segment: first in class ) . Total number of therapeutic drugs granted regulatory marketing approval. Region and period are columns on every record, not slices.
- Limitations
- Values are shown as published; StatOrigin does not revise, fill gaps or convert currencies.
- Verification
- Each value, unit, period and place was checked against its source evidence before publication. See the methodology and the corrections process.
Sources · 5 documents
| Document | Publisher | Published | Data points |
|---|---|---|---|
| 2025年我国批准创新药76个 对外授权超千亿美元 | MOFCOM | — | 1 |
| 创新高！去年我国批准创新药76个 对外授权破千亿美元 | NHSA | — | 1 |
| Measures facilitate approval of 48 first-in-class innovative drugs | NMPA | — | 3 |
| China approves 48 innovative drugs in 2024 | NMPA | — | 1 |
| Measures facilitate approval of 48 first-in-class innovative drugs | State Council | — | 3 |
Other slices of drug approvals
- New active substance approvals 6 new active substance
- Innovative drug approvals 5 innovative
- Novel drug approvals 3 novel
- Pediatric medicine approvals 3 pediatric
- Rare disease medicine approvals 3 rare disease
- Approved innovative drugs designated as breakthrough therapies 2 breakthrough therapy
- Common new active substance approvals across major regulatory authorities (multi-year total) 2 cumulative · common across authorities · new active substance
- Domestic first-in-class drug approvals 2 domestic · first in class
- Domestic innovative biological product approvals 2 domestic · innovative biologic
- Domestic innovative chemical drug approvals 2 domestic · innovative chemical
- Domestic innovative drug approvals (half year) 2 domestic · innovative
- Domestic share of approved innovative biological products 2 domestic · innovative biologic
Frequently asked questions
What is the latest first-in-class drug approvals?
China: 11 in 2025, −77.1% on 2024.
Where does this data come from?
From 5 documents published by NHSA, MOFCOM, State Council and 1 more. Every figure on this page links to its record, which preserves the original source evidence.
How often is it updated?
Annual. The newest published period is 2025; the next release should cover 2026. A new figure appears here once the publisher releases it and it passes verification.
Can I use this data?
Yes. StatOrigin publishes it under CC BY 4.0: you may copy, chart and republish it, including commercially, with attribution to StatOrigin and to the original publisher.
Cite this page
Cite the page as a data set, or open any record to cite one figure: each record carries APA, MLA, Chicago and BibTeX forms that credit the original publisher.
StatOrigin. (2026). First-in-class drug approvals [Data set]. Retrieved October 28, 2026, from https://statorigin.org/indicators/first-in-class-drug-approvals
"First-in-class drug approvals." StatOrigin, 2026, https://statorigin.org/indicators/first-in-class-drug-approvals. Accessed 28 Oct. 2026.
StatOrigin. "First-in-class drug approvals." Data set, 2026. Accessed October 28, 2026. https://statorigin.org/indicators/first-in-class-drug-approvals.
@misc{statorigin_first_in_class_drug_approvals_2026, title = {First-in-class drug approvals}, author = {{StatOrigin}}, year = {2026}, url = {https://statorigin.org/indicators/first-in-class-drug-approvals}, note = {Data set. Accessed 2026-10-28} }